Infliximab treatment for refractory Kawasaki syndrome
- 31 May 2005
- journal article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 146 (5), 662-667
- https://doi.org/10.1016/j.jpeds.2004.12.022
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- Coronary risk factors in Kawasaki disease treated with additional gammaglobulinArchives of Disease in Childhood, 2004
- Plasma exchange for refractory Kawasaki diseaseEuropean Journal of Pediatrics, 2004
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentThe New England Journal of Medicine, 2001
- InfliximabDrugs, 2000
- Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroidsThe Journal of Pediatrics, 1996
- Evaluation of the cytokine response in Kawasaki diseaseThe Pediatric Infectious Disease Journal, 1995
- Gamma globulin re-treatment in Kawasaki diseaseThe Journal of Pediatrics, 1993
- Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-γ in Kawasaki disease involved coronary-artery lesionsClinical Immunology and Immunopathology, 1990
- Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki diseaseClinical Immunology and Immunopathology, 1988
- The Treatment of Kawasaki Syndrome with Intravenous Gamma GlobulinThe New England Journal of Medicine, 1986